Gainplan’s Aerie Pharmaceuticals AERI Stock Holding History

Gainplan’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,500	Closed	-$277K	–	31
2018 Q3	$277K	Buy	+4,500	New	+$289K	0.15%	15
2017 Q4	–	Sell	-6,000	Closed	-$292K	–	23
2017 Q3	$292K	Buy	6,000 +1,600	+36%	+$87.3K	0.15%	8
2017 Q2	$231K	Buy	+4,400	New	+$205K	0.15%	6

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Gainplan's AERI Position: Q4 2018 in Review

Gainplan sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 4,500 shares — an estimated $277K sold.

Gainplan first reported a position in AERI in Q2 2017 and held it in 3 quarters. The position peaked at $292K in Q3 2017. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Gainplan reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Gainplan sold 4,500 Aerie Pharmaceuticals shares in Q4 2018, an estimated $277K.
Gainplan first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 3 quarters.
Gainplan's Aerie Pharmaceuticals position peaked at $292K in Q3 2017.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Gainplan's 13F filing for Q4 2018, filed 8 Feb 2019.